Product Description
Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in various tumor types as a single agent and in combination with other chemotherapeutic agents. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16291410/)
Mechanisms of Action: DHFR Antagonist,TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Lymphoma | Lung Cancer | Mesothelioma | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Pleural Cancer | Small Cell Lung Cancer | Oncology Unspecified | Mesothelioma | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Pleural Cancer | Oncology Unspecified
Known Adverse Events: Stomatitis | Pharyngitis | Anemia | Thrombocytopenia | Neutropenia | Dyspnea | Anorexia | Asthenia | Constipation | Diarrhea
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 49
Highest Development Phases
Phase 3: Lung Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Phase 2: Adenocarcinoma|Biliary Tract Cancer|Brain Cancer|Central Nervous System Cancer|Ependymoma|Glioma|Medulloblastoma|Neuroblastoma|Osteosarcoma|Primary Central Nervous System Lymphoma|Rhabdomyosarcoma|Sarcoma, Ewing|Small Cell Lung Cancer
Phase 1: Chordoma|Head and Neck Cancer|Melanoma|Meningeal Cancer|Meningeal Carcinomatosis|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IS24103 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer|Meningeal Carcinomatosis|Small Cell Lung Cancer|Meningeal Cancer |
2029-11-30 |
|
| 2023-506714-43-00 | P2 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2028-04-30 |
|
| D7988C00001 | P3 |
Unknown Status |
Mesothelioma |
2028-04-03 |
|
| CHIMERA | P2 |
Unknown Status |
Mesothelioma |
2027-03-31 |